AI and digital Innovation

Function

• Research impetus for German biotechnology in areas such as drug discovery and clinical translation and development, acceleration of research cycles through generative AI, cost reductions through process optimization, and time-to-market improvements through increasing digitalization
• Development of new manufacturing processes through AI and transformation of existing processes through digitalization and AI
• Data use in a broad ecosystem with other market participants
• Promotion of the biotech SME and start-up ecosystem instead of increasing bureaucratic hurdles in Germany, including through:
  • Free, privileged access to EHDS and research data spaces (national and EU)
  • Free, privileged access to AI models in the life sciences sector (EU and national)
  • Free, privileged access to public/government bio databases (national and EU)